Moreau-Bachelard, C.; Campion, L.; Robert, M.; Kerdraon, O.; Renaudeau, C.; Aumont, M.; Classe, J.-M.; Campone, M.; Frénel, J.-S.
Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer Patients. Cancers 2020, 12, 3725.
https://doi.org/10.3390/cancers12123725
AMA Style
Moreau-Bachelard C, Campion L, Robert M, Kerdraon O, Renaudeau C, Aumont M, Classe J-M, Campone M, Frénel J-S.
Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer Patients. Cancers. 2020; 12(12):3725.
https://doi.org/10.3390/cancers12123725
Chicago/Turabian Style
Moreau-Bachelard, Camille, Loïc Campion, Marie Robert, Olivier Kerdraon, Céline Renaudeau, Maud Aumont, Jean-Marc Classe, Mario Campone, and Jean-Sébastien Frénel.
2020. "Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer Patients" Cancers 12, no. 12: 3725.
https://doi.org/10.3390/cancers12123725
APA Style
Moreau-Bachelard, C., Campion, L., Robert, M., Kerdraon, O., Renaudeau, C., Aumont, M., Classe, J.-M., Campone, M., & Frénel, J.-S.
(2020). Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer Patients. Cancers, 12(12), 3725.
https://doi.org/10.3390/cancers12123725